References
- Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma 2002;43:1715–1727.
- Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood 1996;88:756.
- Estey EH. Treatment of relapsed and refractory acute myeloid leukemia. Leukemia 2000;14:476–479.
- Giralt S, Saliba RM, Rondon G, et al Outcomes of allogeneic stem cell transplant in patients with myeloid leukemias over 65 years of age. Rationale for aggressive therapy with curative intent. Blood (Suppl) 2008;112:2153 (Abstract).
- McClune B, Weisdorf DJ, DiPErsio JF, et al Non-myeloablative hematopoietic stem cell transplantation in older patients with AML and MDS: results from the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood (Suppl) 2008;112:346 (Abstract).
- Koca E, Saliba RM, de Lima M, et al Impact of pretransplant cytogenetics and marrow remission status on outcome of patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic stem cell transplantation conditioned with busulfan and fludarabine. Blood (Suppl) 2008;112:341 (Abstract).
- Kantarjian H, Gandhi V, Cortes J, et al Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379–2386.
- Faderl S, Ravandi F, Huang X, et al A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638–1645.
- Gidwani P, Ramesh KH, Liu Y, Kolb EA. The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report. Chemotherapy 2008;54:120–124.
- Blum KA, Hamadani M, Phillips GS, et al Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:349–356.
- Martin MG, Uy GL, Procknow E, et al Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. Bone Marrow Transplant 2009 Jul; 44(1)13–7.
- Cheson B, Vena D, Foss F, Sorensen JM. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994;12:2216–2228.